{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:59:22Z","timestamp":1760241562182,"version":"build-2065373602"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01552-5","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:04:30Z","timestamp":1752570270000},"page":"792-799","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and pharmacokinetics of FCN-437c, a novel cyclin-dependent kinase 4\/6 inhibitor, in Chinese patients with hepatic impairment"],"prefix":"10.1007","volume":"43","author":[{"given":"Jia","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingrui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoran","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"1552_CR1","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1158\/0008-5472.Can-23-3704","volume":"84","author":"W Li","year":"2024","unstructured":"Li W et al (2024) CDK4\/6 Alters TBK1 Phosphorylation to Inhibit the STING Signaling Pathway in Prostate Cancer. Cancer Res 84:2588\u20132606. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-3704","journal-title":"Cancer Res"},{"key":"1552_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216956","volume":"593","author":"L Dong","year":"2024","unstructured":"Dong L et al (2024) Targeting STAT3 potentiates CDK4\/6 inhibitors therapy in head and neck squamous cell carcinoma. Cancer Lett 593:216956. https:\/\/doi.org\/10.1016\/j.canlet.2024.216956","journal-title":"Cancer Lett"},{"key":"1552_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216968","volume":"593","author":"S Belli","year":"2024","unstructured":"Belli S et al (2024) EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4\/6 inhibitors in ER+ breast cancer. Cancer Lett 593:216968. https:\/\/doi.org\/10.1016\/j.canlet.2024.216968","journal-title":"Cancer Lett"},{"key":"1552_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e31583","volume":"10","author":"F Tong","year":"2024","unstructured":"Tong F, Lu Y, Ma HF, Shen J (2024) Comparative efficacy and safety of CDK4\/6 inhibitors combined with endocrine therapies for HR+\/HER2-breast cancer: Systematic review and network meta-analysis. Heliyon 10:e31583. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31583","journal-title":"Heliyon"},{"key":"1552_CR5","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/1535-7163.Mct-23-0296","volume":"23","author":"AM Kase","year":"2024","unstructured":"Kase AM et al (2024) Patient-Derived Tumor Xenograft Study with CDK4\/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer. Mol Cancer Ther 23:823\u2013835. https:\/\/doi.org\/10.1158\/1535-7163.Mct-23-0296","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1552_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3390\/cancers16050975","volume":"16","author":"N Sultana","year":"2024","unstructured":"Sultana N, Elford HL, Faridi JS (2024) Targeting the Cell Cycle, RRM2 and NF-\u03baB for the Treatment of Breast Cancers. Cancers (Basel) 16(5):975. https:\/\/doi.org\/10.3390\/cancers16050975","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1552_CR7","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.3390\/ijms25074060","volume":"25","author":"A Lashen","year":"2024","unstructured":"Lashen A et al (2024) The Clinicopathological Significance of the Cyclin D1\/E1-Cyclin-Dependent Kinase (CDK2\/4\/6)-Retinoblastoma (RB1\/pRB1) Pathway in Epithelial Ovarian Cancers. Int J Mol Sci 25(7):4060. https:\/\/doi.org\/10.3390\/ijms25074060","journal-title":"Int J Mol Sci"},{"key":"1552_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s40001-024-01882-9","volume":"29","author":"L Mao","year":"2024","unstructured":"Mao L et al (2024) Antitumour effects of artesunate via cell cycle checkpoint controls in human oesophageal squamous carcinoma cells. Eur J Med Res 29:293. https:\/\/doi.org\/10.1186\/s40001-024-01882-9","journal-title":"Eur J Med Res"},{"key":"1552_CR9","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1016\/j.molcel.2023.10.020","volume":"83","author":"R Foy","year":"2023","unstructured":"Foy R et al (2023) Oncogenic signals prime cancer cells for toxic cell overgrowth during a G1 cell cycle arrest. Mol Cell 83:4047-4061.e4046. https:\/\/doi.org\/10.1016\/j.molcel.2023.10.020","journal-title":"Mol Cell"},{"key":"1552_CR10","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202400769R","volume":"38","author":"S Cavalu","year":"2024","unstructured":"Cavalu S et al (2024) Cell cycle machinery in oncology: A comprehensive review of therapeutic targets. Faseb j 38:e23734. https:\/\/doi.org\/10.1096\/fj.202400769R","journal-title":"Faseb j"},{"key":"1552_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2024.106601","volume":"172","author":"T Yoshimori","year":"2024","unstructured":"Yoshimori T et al (2024) Abemaciclib-induced epithelial-mesenchymal transition mediated by cyclin-dependent kinase 4\/6 independent of cell cycle arrest pathway. Int J Biochem Cell Biol 172:106601. https:\/\/doi.org\/10.1016\/j.biocel.2024.106601","journal-title":"Int J Biochem Cell Biol"},{"key":"1552_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","volume":"81","author":"CL Braal","year":"2021","unstructured":"Braal CL et al (2021) Inhibiting CDK4\/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs 81:317\u2013331. https:\/\/doi.org\/10.1007\/s40265-020-01461-2","journal-title":"Drugs"},{"key":"1552_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/17425255.2018.1541347","volume":"14","author":"JR Choo","year":"2018","unstructured":"Choo JR, Lee SC (2018) CDK4-6 inhibitors in breast cancer: current status and future development. Expert Opin Drug Metab Toxicol 14:1123\u20131138. https:\/\/doi.org\/10.1080\/17425255.2018.1541347","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1552_CR14","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.7150\/jca.48944","volume":"11","author":"M Lin","year":"2020","unstructured":"Lin M, Chen Y, Jin Y, Hu X, Zhang J (2020) Comparative Overall Survival of CDK4\/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. J Cancer 11:7127\u20137136. https:\/\/doi.org\/10.7150\/jca.48944","journal-title":"J Cancer"},{"key":"1552_CR15","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/gutjnl-2016-312268","volume":"66","author":"J Bollard","year":"2017","unstructured":"Bollard J et al (2017) Palbociclib (PD-0332991), a selective CDK4\/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut 66:1286\u20131296. https:\/\/doi.org\/10.1136\/gutjnl-2016-312268","journal-title":"Gut"},{"key":"1552_CR16","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1007\/s12094-024-03510-8","volume":"26","author":"N Chavarr\u00eda Piudo","year":"2024","unstructured":"Chavarr\u00eda Piudo N et al (2024) Retrospective registry of patients with locally advanced\/metastatic HR(+)\/HER2(-) breast cancer treated in clinical practice in Andalusia. Clin Transl Oncol 26:3131\u20133141. https:\/\/doi.org\/10.1007\/s12094-024-03510-8","journal-title":"Clin Transl Oncol"},{"key":"1552_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jare.2021.07.012","volume":"37","author":"S Mubarik","year":"2022","unstructured":"Mubarik S et al (2022) Epidemiological and sociodemographic transitions of female breast cancer incidence, death, case fatality and DALYs in 21 world regions and globally, from 1990 to 2017: An Age-Period-Cohort Analysis. J Adv Res 37:185\u2013196. https:\/\/doi.org\/10.1016\/j.jare.2021.07.012","journal-title":"J Adv Res"},{"key":"1552_CR18","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1097\/cm9.0000000000003442","volume":"137","author":"Y Wu","year":"2024","unstructured":"Wu Y et al (2024) Comparative analysis of cancer statistics in China and the United States in 2024. Chin Med J 137:3093\u20133100. https:\/\/doi.org\/10.1097\/cm9.0000000000003442","journal-title":"Chin Med J"},{"key":"1552_CR19","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1007\/s12094-024-03399-3","volume":"26","author":"H Pla","year":"2024","unstructured":"Pla H et al (2024) Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4\/6 inhibitors in a multicentre cohort. Clin Transl Oncol 26:1748\u20131758. https:\/\/doi.org\/10.1007\/s12094-024-03399-3","journal-title":"Clin Transl Oncol"},{"key":"1552_CR20","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1080\/14796694.2024.2350294","volume":"20","author":"A Brufsky","year":"2024","unstructured":"Brufsky A et al (2024) Identifying drivers of first-line HR+\/HER2- metastatic breast cancer treatment choices. Future Oncol 20:2165\u20132177. https:\/\/doi.org\/10.1080\/14796694.2024.2350294","journal-title":"Future Oncol"},{"key":"1552_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103466","volume":"9","author":"F Marm\u00e9","year":"2024","unstructured":"Marm\u00e9 F et al (2024) Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B. ESMO Open 9:103466. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103466","journal-title":"ESMO Open"},{"key":"1552_CR22","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1158\/1538-7445.Am2019-4425","volume":"79","author":"S Lin","year":"2019","unstructured":"Lin S et al (2019) Abstract 4425: FCN-437: A novel, potent and selective oral inhibitor of CDK4\/6 for the treatment of solid tumors. Can Res 79:4425\u20134425. https:\/\/doi.org\/10.1158\/1538-7445.Am2019-4425","journal-title":"Can Res"},{"key":"1552_CR23","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s10637-021-01133-2","volume":"39","author":"J Zhang","year":"2021","unstructured":"Zhang J et al (2021) Phase 1a study of the CDK4\/6 inhibitor, FCN-437c, in Chinese patients with HR + \/HER2- advanced breast cancer. Invest New Drugs 39:1549\u20131558. https:\/\/doi.org\/10.1007\/s10637-021-01133-2","journal-title":"Invest New Drugs"},{"issue":"20","key":"1552_CR24","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.3390\/cancers14204996","volume":"14","author":"A Patnaik","year":"2022","unstructured":"Patnaik A et al (2022) A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4\/6 Inhibitor. Patients with Advanced Solid Tumors. Cancers (Basel) 14(20):4996. https:\/\/doi.org\/10.3390\/cancers14204996","journal-title":"Patients with Advanced Solid Tumors. Cancers (Basel)"},{"key":"1552_CR25","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/jcph.128","volume":"53","author":"Y Chang","year":"2013","unstructured":"Chang Y, Burckart GJ, Lesko LJ, Dowling TC (2013) Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels. J Clin Pharmacol 53:962\u2013966. https:\/\/doi.org\/10.1002\/jcph.128","journal-title":"J Clin Pharmacol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01552-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01552-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01552-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:03:44Z","timestamp":1760195024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01552-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1552"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01552-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}